28 May 2026
28 May 2026
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the clinical pipeline.
The US biotech’s technology integrates multiple protein modalities to simultaneously target a variety of disease mechanisms.
Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.
With $14.2bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.
The EMA’s CHMP delivered two positive opinions, which will likely see an expansion of Novo Nordisk’s Wegovy offerings in Europe.
The HAE pharmaceutical landscape is set for unprecedented expansion as a large proportion of pipeline drugs are found in Phase III. Emerging technologies such as CRISPR and siRNA platforms may provide meaningful differentiation in an otherwise competitive landscape.
Autobahn expects topline data from the ongoing Phase II AMPLIFY-BD trial in adjunctive bipolar depression in the second quarter of 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
